Protein kinase C-β mediates lipoprotein-induced generation of PAI-1 from vascular endothelial cells

American Journal of Physiology - Endocrinology and Metabolism

Volumn 278, Issue 4 41-4, 2000, Pages

  Ren, Song ^a   Shatadal, Shalini ^a   Shen, Garry X ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Lipoprotein(a); Low density lipoproteins; Oxidation; Plasminogen activator inhibitor 1

Indexed keywords

APOLIPOPROTEIN A; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN KINASE C;

ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LIPID OXIDATION; PRIORITY JOURNAL; PROTEIN SYNTHESIS; VASCULAR ENDOTHELIUM;

EID: 0034004141     PISSN: 01931849     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpendo.2000.278.4.e656     Document Type: Article

References (42)

1. Arnman V, Nilsson A, Stemme S, Risberg B, and Rymo L. Expression of plasminogen activator inhibitor-1 mRNA in healthy, atherosclerotic and thrombotic arteries and veins. Thromb Res 74: 487-499, 1994.
2. Austin MA and Hokanson JE. Epidemiology of triglyceride, small dense low density lipoprotein, and lipoprotein(a) as risk factor for coronary heart disease. Med Clin North Am 78: 99-115, 1994.
3. Ballas LM, Hall SE, Winneroski LL, and Faul MM. (S)-13-[(monomethylamino)]-10,11,14,15-tetrahydro-4,9,16,21-dime-theno-1H,13H- dibenzo[E,K] pyrrolo-[3,4-H][1,4,13]oxadiazacyclohexadecine-1,3(2H)-dione (LY333531) and related analogs. Isozyme selective inhibitors of protein kinase Cβ (PKCβ). J Med Chem 39: 2664-2671, 1996.
4. Berg K. Lp(a) lipoprotein: an overview. Chem Phys Lipids 67-68:9-16, 1994.
5. Chautan M, Latron Y, Anfosso F, Alessi MC, Lafont H, Juhan-Vague I, and Nalbone G. Phospatidylinositol turnover during stimulation of plasminogen activator inhibitor-1 secretion induced by oxidized low-density lipoproteins in human endothelial cells. J Lipid Res 34: 101-110, 1993.
6. Chen SJ, Klann E, Gower MC, Powell CM, Sessoms JS, and Sweatt JD. Studies with synthetic peptide substrates derived from the neuronal protein neurogranin reveal structural determinants of potency and selectivity for protein kinase C. Biochemistry 32: 1032-1039, 1993.
7. Cortellaro M, Cafrancesco E, Boschetti C, Mussoni L, Ponati MB, Cardillo M, Garbrielli L, Lombard B, and Specchia G. Increased fibrin turnover and high PAI-1 antigen as predicator of ischemic event in atherosclerotic patients. The PLAT group. Arterioscler Thromb Vasc Biol 13: 1412-1417, 1993.
8. Emeis JJ and Kooistra T. Interleukin 1 and lipopolysaccharide induce an inhibitor of tissue-type plasminogen activator in vivo and in cultured endothelial cells. J Exp Med 163: 1260-1266, 1986.
9. Etingin OR, Hajjar DP, Hajjar KA, Harpel PC, and Nachman RL. Lipoprotein(a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. J Biol Chem 266: 2456-2465, 1991.
10. George R, Barber DL, and Schneider WJ. Characterization of the chicken oocyte receptor for low and very low density lipoproteins. J Biol Chem 262: 16838-16847, 1987.
11. Glulich-Henn J and Muller-Berghaus, G. Regulation of endothelial tissue plasminogen activator and plasminogen activator inhibitor type 1 by diacylglycerol, phorbol ester, and thrombin. Blut 61: 38-44, 1990.
12. Hamsten A, De Faire U, Walldius G, Dahlen G, Szamosi A, Blomback M, Landou C, and Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 2: 3-9, 1987.
13. Ishii H, Jirousek MR, Koya D, Takagi C, Xia P, Clermont A, Bursell S-E, Kern TS, Dallas LM, Heath WF, Stramm LE, Feener EP, and King GL. Amelioration of vascular dysfunctions in diabetic rats by an oral PKCβ inhibitor. Science 272: 728-731, 1996.
14. Keneko T, Wada H, Wakita Y, Minamikawa K, Nakase T, Mori Y, Deguchi K, and Shirakawa S. Enhanced tissue factor activity and plasminogen activator inhibitor-1 antigen in human umbilical vein endothelial cells incubated with lipoproteins. Blood Coagul Fibrinolysis 5: 385-392, 1994.
15. Kobayashi E, Nakano H, Morimoto M, and Tamaoki T. Calphostin C (UCN-1028C), a novel microbal compound, is a highly potent and specific inhibitor of protein kinase C. Biochem Biophys Res Commun 159: 548-553, 1989.
16. Kobayashi K, Watanabe J, Umeda F, and Nawata H. Glycation accelerates the oxidation of low density lipoprotein by copper ions. Endocr J 42: 461-465, 1995.
17. Konkle BA and Ginsburg D. The addition of endothelial cell growth factor and heparin to human umbilical vein endothelial cell cultures decreases plasminogen activator inhibitor-1 expression. J Clin Invest 82: 579-585, 1988.
18. Kugiyama K, Sakamoto T, Misumi I, Sugiyama S, Ohgushi M, Ogawa H, Horiguchi M, and Yasue H. Transferable lipids in oxidized low density lipoprotein stimulate plasminogen activator inhibitor-1 and inhibit tissue-type plasminogen activator release from endothelial cells. Circ Res 73: 335-343, 1993.
19. Latron Y, Chautan M, Anfosso F, Alessi MC, Nalbone G, Lafont H, and Juhan-Vague I. Stimulating effect of oxidized low density lipoprotein on plasminogen activator inhibitor-1 synthesis by endothelial cells. Arterioscler Thromb 11: 182-189, 1991.
20. Levin EG, Marzek U, Anderson J, and Harker LA. Thrombin stimulates tissue plasminogen activator release from cultured human endothelial cells. J Clin Invest 74: 1988-1995, 1984.
21. Lopez S, Peiretti F, Morange P, Laouar A, Fossat C, Bonardo B, Huberman E, Juhan-Vague I, and Nalbone G. Activation of plasminogen activator inhibitor-1 synthesis by phorbol esters in human promyelocytes HL-60-roles of PKCbeta and MAPK p42. Thromb Haemost 81: 415-422, 1999.
22. Liu SY, Choy S, Dembinski TC, Hatch GM, Mymin D, Shen X, Angel A, Choy PC, and Man RYK. Alteration of lysophosphatidylcholine content in low density lipoprotein after oxidative modification: relationship to endothelium dependent relaxation. Cardiovasc Res 28: 1476-1481, 1994.
23. Naruszewicz M, Giroux LM, and Davignon J. Oxidative modification of Lp(a) causes changes in the structure and biological properties of Lp(a). Chem Phys Lipids 67-68: 167-174, 1994.
24. Naruszewicz M, Selinger E, and Davignon J. Oxidative modification of lipoprotein(a) and the effect of beta-carotene. Metabolism 41: 1215-1224, 1992.
25. Ohkawa H, Ohishi N, and Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 95: 351-358, 1979.
26. Ren S, Man RYK, Angel A, and Shen GX. Oxidative modification enhances lipoprotein(a)-induced overproduction of plasminogen activator inhibitor-1 in cultured vascular endothelial cells. Atherosclerosis 128: 1-10, 1997.
27. Schneider DJ and Soble BE. Synergistic augmentation of expression of plasminogen activator inhibitor type-1 induced by insulin, very low density lipoproteins and fatty acids. Coron Artery Dis 7: 813-817, 1996.
28. Shen GX. Vascular cell-derived fibrinolytic regulators and atherothrombotic vascular disorders. Int J Mol Med 1: 399-408, 1998.
29. Shen GX, Mymin D, Dembinski T, Krahn A, and Angel A. Polymorphism and peripheral levels of apolipoprotein(a) in polygenic hypercholesterolemia and combined hyperlipidemia. Clin Invest Med 18: 33-41, 1995.
30. Shen GX and Ren S. Role of oxidative modification in glycated LDL-induced generation of fibrinolytic regulators in vascular endothelial cells (Abstract). Diabetes 48: A134, 1999.
31. Sheu FS, Huang FL, and Huang KP. Differential responses of protein kinase C substrate (MARCKS, neuromodulin, and neurogranin) phosphorylation to calmodulin and S100. Arch Biochem Biophys 316: 335-342, 1995.
32. Snyder ML, Polacek D, Scanu AM, and Fless GM. Comparative binding and degradation of lipoprotein(a) and low density lipoprotein by human monocyte-derived macrophages. J Biol Chem 267: 339-346, 1992.
33. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, and Witztum JL. Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 320: 915-924, 1989.
34. Steinbrecher UP, Parthasarathy S, Leake DS, Witztum JL, and Steinberg D. Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc Natl Acad Sci USA 81: 3883-3887, 1984.
35. Stiko-Rahm A, Wiman B, Hamsten A, and Nilsson J. Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein. Arteriosclerosis 10: 1067-1073, 1990.
36. Takahara N, Kashiwagi A, Maegawa H, and Shigeta Y. Lysophosphatidylcholine stimulates the expression and production of MCP-1 by human vascular endothelial cells. Metabolism 45: 559-564, 1996.
37. Tremoli E, Camera M, Maderna P, Sironi L, Prati L, Colli S, Piovella F, Bernini F, Corsini A, and Mussoni L. Increased synthesis of plasminogen activator inhibitor-1 by cultured human endothelial cells exposed to native and modified LDLs: an LDL receptor-independent phenomenon. Arterioscler Thromb 13: 338-346, 1993.
38. Van Hinsberg VW, Bertibna RM, van Wijngaarden A, van Tilburg NH, Emeis JJ, and Haverkate F. Activated protein C decreases plasminogen activator-inhibitor activity in endothelial cell-conditioned medium. Blood 65: 444-451, 1985.
39. Wada H, Kaneko T, Wakita Y, Minamikawa K, Nagaya S, Tamaki S, Deguchi K, and Shirakawa S. Effect of lipoproteins on tissue factor and PAI-II antigen in human monocytes and macorphages. Int J Cardiol 47, Suppl 1: S21-S25, 1994.
40. Wu LL. Review of risk factors for cardiovascular diseases. Ann Clin Lab Sci 29: 127-133, 1999.
41. Yorimitsu K, Saito T, Toyozaki T, Ishide T, Ohnuma N, and Inagaki Y. Immunohistochemical localization of plasminogen activator inhibitor-1 in human coronary athrosclerosis lesions involved in acute myocardial infarction. Heart Vessels 8: 160-162, 1993.
42. Zhang J, Ren S, Sun D, and Shen GX. Influence of glycation on LDL-induced generation of fibrinolytic regulators in vascular endothelial cells. Arterioscler Thromb Vasc Biol 18: 1140-1148, 1998.